Frequently Asked Questions about Moderna, Inc. (MRNA)

Name: Moderna, Inc. (MRNA) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Moderna, Inc. (MRNA) do?

Accepted Answer

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its r...

Question 2

Is Moderna, Inc. (MRNA) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of MRNA reveals an Altman Z-Score of 3.81 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($1.94B most recent), help investors decide if MRNA fits their risk profile.

Question 3

What is the current P/E ratio for MRNA?

Accepted Answer

As of the latest trading session, Moderna, Inc. (MRNA) has a trailing P/E ratio of -6.82.

Question 4

Who is the CEO of Moderna, Inc.?

Accepted Answer

The current Chief Executive Officer of Moderna, Inc. is Stéphane Bancel.

Question 5

What was MRNA's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Moderna, Inc. reported annual revenues of $1.94B (2025), $3.20B (2024), $6.85B (2023), $18.88B (2022), $17.74B (2021) respectively.

Question 6

Does MRNA pay a dividend?

Accepted Answer

Moderna, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does MRNA have?

Accepted Answer

In its latest reporting period, Moderna, Inc. generated $-2.06B in Free Cash Flow against a total debt load of $1.92B.

Question 8

What is the Price-to-Book (P/B) ratio of Moderna, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Moderna, Inc. (MRNA) is currently 2.22.

Question 9

What is the Price-to-Sales (P/S) ratio of MRNA?

Accepted Answer

Based on trailing twelve-month data, Moderna, Inc. (MRNA) trades at a Price-to-Sales (P/S) ratio of 9.98.

Question 10

What is Moderna, Inc.'s Return on Equity (ROE)?

Accepted Answer

Moderna, Inc. (MRNA) has a Return on Equity (ROE) of -30.15%, representing its profitability relative to shareholder equity.

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	1.9B	1.1B	-3.1B	-2.8B	-7.26
2024-12	3.2B	1.7B	-3.9B	-3.6B	-9.27
2023-12	6.8B	2.2B	-4.2B	-4.7B	-12.34
2022-12	18.9B	13.5B	9.4B	8.4B	21.26
2021-12	17.7B	15.1B	13.3B	12.2B	30.31

Period	Revenue	Gross Profit	Op. Income	Net Income	EPS
2025-12	1.9B	1.1B	-3.1B	-2.8B	-7.26
2024-12	3.2B	1.7B	-3.9B	-3.6B	-9.27
2023-12	6.8B	2.2B	-4.2B	-4.7B	-12.34
2022-12	18.9B	13.5B	9.4B	8.4B	21.26
2021-12	17.7B	15.1B	13.3B	12.2B	30.31